Virobay Inc. and LEO Pharma initiated a collaboration in early January 2012 to develop an oral treatment in psoriasis. Link to press release
At Virobay, we seek collaborative partnerships for certain of our product candidates that target large indications outside of our strategic interests.
As with our collaboration with LEO, we believe these collaborations will provide validation of our technology, significant research funding to advance our pipeline and access to development, manufacturing and commercial expertise and capabilities.
Why partner with Virobay
- Our focus is to address significant unmet medical needs for the treatment of neuropathic pain autoimmune diseases and fibrosis
- We have extensive knowledge and experience designing selective cathepsin inhibitors
- We have decades of experience in drug discovery and development, including leadership roles at AcelRx Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pharmacyclics, Inc., Pfizer, Inc., Rigel Pharmaceuticals, Inc., Sugen, Inc. and Schering-Plough Corporation
- We are highly collaborative with partners
For information about our partnership opportunities, please contact the Virobay Business Development Department.
Attn: Business Development
1360 Willow Road, Suite 100
Menlo Park, CA 94025